636
Participants
Start Date
June 21, 2022
Primary Completion Date
May 31, 2026
Study Completion Date
May 31, 2029
AK104
q3w iv
EBRT
45-50.4Gy
BT
≥80Gy
cisplatin
qw iv
Placebo
q3w iv
Peking Union Medical College Hospital, Beijing
Fudan University Shanghai Cancer Center, Shanghai
Women's Hospital School Of Medicine Zhejiang University, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Xiangya Hospital Central South University, Changsha
Hubei Cancer Hospital, Wuhan
Guizhou Cancer Hospital, Guiyang
West China Second University Hospital, Chengdu
Hunan cancer hospital, Changsha
Lead Sponsor
Akeso
INDUSTRY